 Magenta Therapeutics NASDAQ:MGTA was downgraded by research analysts at BidaskClub from a hold rating to a sell rating in a research note issued to investors on Saturday, BidAskClub reports. Other equities analysts also recently issued research reports about the company. Wedbush reiterated a buy rating and issued a 22.00 price objective on shares of Magenta ... 